Submit Your Article CMED MEACR meeting
Home Print this page Email this page Users Online: 308
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2013  |  Volume : 2  |  Issue : 3  |  Page : 218-222

Primary extranodal non-Hodgkin's lymphoma: A retrospective analysis of its clinicopathological features and treatment outcomes in a tertiary cancer center of eastern India


1 Department of Radiotherapy, Medical College and Hospitals, Kolkata, West Bengal, India
2 Department of Radiotherapy, Radha Gobinda Kar Medical College and Hospital, Kolkata, West Bengal, India
3 Department of Medicine, Nilratan Sircar Medical College and Hospital, Kolkata, West Bengal, India

Correspondence Address:
Bitoti Chattopadhyay
Flat No. 2G, Nature's Nest, 140, P. G. H. Shah Road, Jadavpur, Kolkata - 700 032, West Bengal
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2278-0513.119269

Rights and Permissions

Background: Primary extranodal non-Hodgkin's Lymphomas (NHL) is an uncommon entity. It is diverse in its presentation, morphology, histology, and immunophenotyping. No clear-cut consensus exists regarding its management. Indian data is lacking regarding biology and treatment of disease. Aim: The aim of this study is to analyze the clinicopathological features and assess treatment modalities utilized and their outcomes in patients with primary extranodal NHL and also the outcome with involved field radiotherapy (IFRT). Settings and Design: This is a retrospective observational study from prerecorded hospital data. Materials and Methods: Cases of primary extranodal NHL attending the radiotherapy outpatient department of our institute during the last 5 years (July 2007-June 2012) were taken for this study. Hospital recorded data were taken and analyzed regarding the demography, clinical features, histopathological features, and treatment modalities and their outcomes. Result: Total 41 patients were identified, out of which six patients did not turn up for any form of treatment. Almost all patients (33 out of 35, 94.28%) received chemotherapy while around 55% (19 out of 35) patients received radiotherapy. During follow-up, around 23% patients had relapsed, that too mostly outside the primary site. Conclusion: Immunohistochemistry is essential in all cases to identify the subset which would respond excellently to rituximab (CD20 positive). IFRT has definite role in the management of extranodal NHL in patients having residual disease following chemotherapy.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2164    
    Printed57    
    Emailed0    
    PDF Downloaded116    
    Comments [Add]    
    Cited by others 1    

Recommend this journal